Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.31 |
| ▸ | ABAT | P80404 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263592 | 0.85 | GAA (0.42) | GAAPKMLOXL2HRH3LOX | |
| Hydrochloric Acid SCHEMBL7214713 | 0.83 | GAA (0.44) | GAAPKMLOXL2HRH3LOX | |
| SCHEMBL318089 | 0.81 | KIF11 (0.41) | GAARAD52NPBWR1CYP2A6 | |
| SCHEMBL10640127 | 0.81 | CBFB (0.41) | — | |
| SCHEMBL24214987 | 0.81 | RAD52 (0.30) | RAD52UBE2N | |
| SCHEMBL14208120 | 0.78 | CNR1 (0.39) | RAD52UBE2NNPBWR1 | |
| SCHEMBL24960591 | 0.77 | ESR1 (0.37) | — | |
| SCHEMBL13625536 | 0.77 | GABRA1 (0.40) | — | |
| SCHEMBL31229543 | 0.75 | KDM4E (0.49) | GAA | |
| SCHEMBL10102945 | 0.75 | KDM4E (0.49) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208951-A1 | A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF | GBR LABORATORIES PRIVATE LIMITED (IN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208951-A1 | A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF | GBR LABORATORIES PRIVATE LIMITED (IN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208951-A1 | A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF | GBR LABORATORIES PRIVATE LIMITED (IN) | 2024-06-27 | — | — | US | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2019-11-21 | — | — | US | disclosed |
| WO-2017132432-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2016144704-A2 | HETEROCYCLIC AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | GAA 568/4885PKM 998/4885RAD52 4681/4885 |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | RORB, RORC, RORA | GAA 370/4885PKM 989/4885RAD52 4628/4885 |
| US-20240208951-A1 | A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF | CYP4A11, CYP4F11, XDH | GAA 2592/4885PKM 279/4885RAD52 4301/4885 |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | GAA 628/4885PKM 2364/4885RAD52 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.